DEF: Glucotrack Seeks Shareholder Approval for Key Capital Raises

Glucotrack, Inc. calls a Special Meeting to approve significant stock issuances for capital raises and ratify its independent auditor.

Summary

• A Special Meeting of Stockholders will be held exclusively online on Thursday, March 12, 2026, at 11:00 a.m. (Eastern Time).
• Stockholders will vote on Proposal 1 to approve the full issuance of common stock to Sixth Borough Capital Fund, LP, which may represent more than 20% of the company's outstanding common stock, as required by Nasdaq Listing Rule 5635(d).
• Proposal 2 seeks approval for the full issuance of shares of common stock issuable upon the exercise of 2,067,182 common warrants issued in a private placement that closed on December 31, 2025, also for Nasdaq compliance.
• Proposal 3 is for the ratification of CBIZ CPAs P.C. as the company's independent registered public accounting firm for the year ended December 31, 2025.
• Proposal 4 is an adjournment proposal, if necessary, to permit further solicitation of proxies or to constitute a quorum.
• The Board of Directors unanimously recommends that stockholders vote FOR all four proposals.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the significant potential for shareholder dilution, the explicit 'going concern' warning from the previous auditor, and identified material weaknesses in internal controls, all of which overshadow the necessary capital raising efforts.

Positives

• The Purchase Agreement with Sixth Borough Capital Fund, LP provides a potential source of up to $20.0 million in capital over a 24-month term.
• The Private Placement with Armistice Capital Master Fund Ltd. involved the issuance of 1,033,591 Pre-Funded Warrants and 2,067,182 Common Warrants, with the exercise of Common Warrants potentially bringing in approximately an additional $8 million.
• The Board of Directors unanimously recommends approval of all proposals, indicating internal alignment on these strategic actions.

Negatives

• Approval of Proposal 1 (Sixth Borough issuance) will have a dilutive effect on existing stockholders' ownership interests and voting power.
• Approval of Proposal 2 (Common Warrants issuance) will result in significant dilution, with the Investor potentially owning approximately 77.29% of the then-outstanding Common Stock after full exercise of all Pre-Funded and Common Warrants.
• The sale of these newly issued shares into the public market could materially and adversely affect the market price of the Common Stock.
• Failure to approve Proposal 2 could jeopardize the company's ability to execute its business plan due to the loss of approximately $8 million in potential funds, potentially leading to liquidation or bankruptcy protection if alternative financing is not secured.
• The company previously identified material weaknesses in internal control over financial reporting related to general IT controls, lack of sufficient accounting personnel, and inadequate segregation of duties for the fiscal year ended December 31, 2024.
• The previous independent registered public accounting firm, Grant Thornton, included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern in its reports for fiscal years ended December 31, 2024, and 2023.

Risks

• Failure to obtain stockholder approval for Proposal 1 will limit the company's ability to issue shares to Sixth Borough Capital Fund, LP in excess of the Exchange Cap (179,792 shares) unless the average price of all shares issued equals or exceeds the September 11 Minimum Price of $4.63 per share.
• Failure to obtain stockholder approval for Proposal 2 means the Investor will not be able to exercise the Common Warrants, potentially resulting in the loss of approximately $8 million in funds, which could jeopardize the company's business plan, prevent sufficient funding for operations, and potentially lead to liquidation or bankruptcy protection.
• Existing stockholders will suffer dilution in ownership interests and voting rights if Proposals 1 and 2 are approved and the associated shares are issued.
• The sale of newly issued shares into the public market could materially and adversely affect the market price of the Common Stock.
• The issuance of Common Stock could have an anti-takeover effect by increasing the number of shares entitled to vote and the number of votes required to approve a change of control.
• Material weaknesses in internal control over financial reporting, including general IT controls, insufficient accounting personnel, and inadequate segregation of duties, pose operational and financial reporting risks.
• The company's ability to continue as a going concern is in substantial doubt, as noted by the previous auditor.

Future Outlook

The company seeks stockholder approval to enable full utilization of a $20.0 million capital facility and to allow the exercise of common warrants that could bring in approximately $8 million, which are crucial for funding its business plan. Failure to secure these approvals could jeopardize future operations, potentially leading to liquidation or bankruptcy.

Management Comments

• The Board of Directors unanimously recommends that stockholders vote FOR Proposals 1, 2, 3 and 4.
• Our Board has determined that the Purchase Agreement with Sixth Borough is in the best interests of the Company and its stockholders because the right to sell shares to Sixth Borough provides the Company with a potential source of capital and the ability to access that capital when and as needed.

Industry Context

StockSavvy.ai notes that companies, particularly those in development or early commercialization stages, often rely on equity financing facilities like the one with Sixth Borough and private placements with warrants to secure necessary capital. The need for shareholder approval for issuances exceeding 20% of outstanding shares at a discount is a standard Nasdaq compliance requirement, reflecting investor protection against excessive dilution without consent. The change in auditors and the previous auditor's going concern opinion, coupled with identified material weaknesses, suggest a company facing significant operational and financial challenges, which is not uncommon for smaller, growth-oriented firms but warrants close scrutiny.

Comparison to Industry Standards

• The reliance on equity lines of credit (ELOCs) and private placements with warrants for capital is a common strategy for smaller, growth-stage companies, particularly those in the biotech or medical device sectors, which often have high R&D costs and uncertain revenue streams. However, the potential for significant dilution (e.g., 77.29% ownership by a single investor post-warrant exercise) is on the higher end compared to typical institutional private placements, which usually aim for less concentrated ownership to maintain liquidity and broader investor appeal.
• The previous auditor's 'going concern' explanatory paragraph and the identified material weaknesses in internal controls (general IT controls, insufficient accounting personnel, inadequate segregation of duties) are red flags that deviate significantly from best practices for established public companies. While not uncommon for very small or newly public entities, these issues indicate a need for substantial improvement in financial infrastructure and oversight, which could impact investor confidence and operational efficiency compared to more mature industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant dilution of ownership and voting power if stock issuance proposals are approved. Potential adverse impact on share price. Risk of company liquidation or bankruptcy if capital raises are not fully realized.
• Employees: Potential impact on job security if the company faces financial distress due to insufficient funding.
• Creditors: Increased risk if the company's financial health deteriorates, potentially impacting ability to repay debts.
• Management/Board: Increased responsibility to address internal control weaknesses and secure necessary funding.

Next Steps

• Hold a Special Meeting of Stockholders on March 12, 2026, to vote on the proposals.
• If Proposal 2 is not approved at the first meeting, the company is obligated to call a meeting every ninety (90) days thereafter to seek Stockholder Approval until it is obtained or the Common Warrants are no longer outstanding.
• File voting results in a Current Report on Form 8-K within four business days after the Special Meeting.
• The Board will reconsider the selection of CBIZ if stockholders do not ratify their appointment.

Key Dates

Recommendation

The filing reveals significant red flags, including a previous 'going concern' warning from the auditor and identified material weaknesses in internal controls, indicating severe financial and operational instability. While the capital raises are crucial, they come with substantial dilution for existing shareholders (one investor potentially owning 77.29% post-warrant exercise), which could severely depress the stock price. The risk of liquidation or bankruptcy if these capital raises are not fully realized presents an existential threat. Given these factors, a seasoned investor would likely recommend selling to avoid further downside risk.

Keywords

Glucotrack, GCTK, SEC filing, DEF 14A, proxy statement, special meeting, stock issuance, Nasdaq Listing Rule 5635(d), dilution, capital raise, Sixth Borough Capital Fund, Armistice Capital, private placement, warrants, pre-funded warrants, auditor ratification, CBIZ CPAs, corporate governance, financial health, risk factors, going concern, internal controls